Literature DB >> 23221002

Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains.

Karina Yusim1, Rebecca Dilan, Erica Borducchi, Kelly Stanley, Elena Giorgi, William Fischer, James Theiler, Joseph Marcotrigiano, Bette Korber, Dan H Barouch.   

Abstract

Despite improved hepatitis C virus (HCV) treatments, vaccines remain an effective and economic option for curtailing the epidemic. Mosaic protein HCV genotype 1 vaccine candidates designed to address HCV diversity were immunogenic in mice. They elicited stronger T-cell responses to NS3-NS4a and E1-E2 proteins than did natural strains, as assessed with vaccine-matched peptides.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23221002      PMCID： PMC3571268          DOI： 10.1128/CVI.00605-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  27 in total

1.  Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Authors:  Angelique A C Lemckert; Shawn M Sumida; Lennart Holterman; Ronald Vogels; Diana M Truitt; Diana M Lynch; Anjali Nanda; Bonnie A Ewald; Darci A Gorgone; Michelle A Lifton; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.

Authors:  Fusheng Li; Uma Malhotra; Peter B Gilbert; Natalie R Hawkins; Ann C Duerr; Juliana M McElrath; Lawrence Corey; Steven G Self
Journal:  Vaccine       Date:  2006-06-27       Impact factor: 3.641

3.  Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens.

Authors:  Sampa Santra; Mark Muldoon; Sydeaka Watson; Adam Buzby; Harikrishnan Balachandran; Kevin R Carlson; Linh Mach; Wing-Pui Kong; Krisha McKee; Zhi-Yong Yang; Srinivas S Rao; John R Mascola; Gary J Nabel; Bette T Korber; Norman L Letvin
Journal:  Virology       Date:  2012-04-21       Impact factor: 3.616

Review 4.  Adaptive immune responses in acute and chronic hepatitis C virus infection.

Authors:  David G Bowen; Christopher M Walker
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

5.  Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.

Authors:  Sampa Santra; Hua-Xin Liao; Ruijin Zhang; Mark Muldoon; Sydeaka Watson; Will Fischer; James Theiler; James Szinger; Harikrishnan Balachandran; Adam Buzby; David Quinn; Robert J Parks; Chun-Yen Tsao; Angela Carville; Keith G Mansfield; George N Pavlakis; Barbara K Felber; Barton F Haynes; Bette T Korber; Norman L Letvin
Journal:  Nat Med       Date:  2010-02-21       Impact factor: 53.440

6.  HCV persistence and immune evasion in the absence of memory T cell help.

Authors:  Arash Grakoui; Naglaa H Shoukry; David J Woollard; Jin-Hwan Han; Holly L Hanson; John Ghrayeb; Krishna K Murthy; Charles M Rice; Christopher M Walker
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

7.  Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection.

Authors:  Kazumoto Murata; Martin Lechmann; Ming Qiao; Toshiaki Gunji; Harvey J Alter; T Jake Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

8.  Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination.

Authors:  Wing-Pui Kong; Lan Wu; Timothy C Wallstrom; Will Fischer; Zhi-Yong Yang; Sung-Youl Ko; Norman L Letvin; Barton F Haynes; Beatrice H Hahn; Bette Korber; Gary J Nabel
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

9.  A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.

Authors:  Ruihong Zeng; Guangxue Li; Shigan Ling; Heqiu Zhang; Zhiyan Yao; Bingshui Xiu; Feng He; Rui Huang; Lin Wei
Journal:  Antiviral Res       Date:  2009-07-29       Impact factor: 5.970

10.  Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Authors:  Dan H Barouch; Maria G Pau; Jerome H H V Custers; Wouter Koudstaal; Stefan Kostense; Menzo J E Havenga; Diana M Truitt; Shawn M Sumida; Michael G Kishko; Janelle C Arthur; Birgit Korioth-Schmitz; Michael H Newberg; Darci A Gorgone; Michelle A Lifton; Dennis L Panicali; Gary J Nabel; Norman L Letvin; Jaap Goudsmit
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422
View more
  12 in total

1.  Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.

Authors:  Andreas Walker; Kathrin Skibbe; Eike Steinmann; Stephanie Pfaender; Thomas Kuntzen; Dominik A Megger; Svenja Groten; Barbara Sitek; Georg M Lauer; Arthur Y Kim; Thomas Pietschmann; Todd M Allen; Joerg Timm
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

2.  Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.

Authors:  Santa Olivera; Angel Perez; Viviana Falcon; Dioslaida Urquiza; Dagmara Pichardo; Gillian Martinez-Donato
Journal:  Arch Virol       Date:  2020-02-03       Impact factor: 2.574

3.  Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.

Authors:  Susanne Ziegler; Kathrin Skibbe; Andreas Walker; Xiaoyu Ke; Falko M Heinemann; Andreas Heinold; Juk Yee Mok; Wim J E van Esch; Dongliang Yang; Matthias Wölfl; Jörg Timm
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

4.  Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.

Authors:  Sultan Abdul-Jawad; Beatrice Ondondo; Andy van Hateren; Andrew Gardner; Tim Elliott; Bette Korber; Tomáš Hanke
Journal:  Mol Ther       Date:  2015-11-19       Impact factor: 11.454

5.  Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine.

Authors:  James Theiler; Hyejin Yoon; Karina Yusim; Louis J Picker; Klaus Fruh; Bette Korber
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

6.  Priming Cross-Protective Bovine Viral Diarrhea Virus-Specific Immunity Using Live-Vectored Mosaic Antigens.

Authors:  Shehnaz Lokhandwala; Xin Fang; Suryakant D Waghela; Jocelyn Bray; Leo M Njongmeta; Andy Herring; Karim W Abdelsalam; Christopher Chase; Waithaka Mwangi
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

7.  Graph-based optimization of epitope coverage for vaccine antigen design.

Authors:  James Theiler; Bette Korber
Journal:  Stat Med       Date:  2017-01-29       Impact factor: 2.373

Review 8.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

9.  The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.

Authors:  Annette von Delft; Timothy A Donnison; José Lourenço; Claire Hutchings; Caitlin E Mullarkey; Anthony Brown; Oliver G Pybus; Paul Klenerman; Senthil Chinnakannan; Eleanor Barnes
Journal:  Vaccine       Date:  2017-12-02       Impact factor: 3.641

Review 10.  Polyvalent vaccine approaches to combat HIV-1 diversity.

Authors:  Bette Korber; Peter Hraber; Kshitij Wagh; Beatrice H Hahn
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 10.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.